Pace of FDA research frustrates CBD advocates
A January article co-authored by U.S. Food and Drug Administration commissioner Stephen Hahn, which calls for more high-quality CBD research, is unlikely to impress many in the hemp industry. CBD advocates have long been frustrated by what they consider the slow pace of research into the cannabis derived compound.
Over the counter CBD use has soared in recent years, with millions of U.S. consumers snapping up an
Log in or become a WeedWeek Member to read this article.
